{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Lobbying and Lobbyists", "name": "subject", "rank": "11", "is_major": "N"}, {"value": "Health Insurance and Managed Care", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Conflicts of Interest", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "National Health Council", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "American Diabetes Assn", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Leukemia & Lymphoma Society", "name": "organizations", "rank": "7", "is_major": "N"}, {"value": "Mylan Inc", "name": "organizations", "rank": "8", "is_major": "N"}, {"value": "National Multiple Sclerosis Society", "name": "organizations", "rank": "9", "is_major": "N"}, {"value": "Pharmaceutical Research and Manufacturers of America", "name": "organizations", "rank": "10", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/09/28/business/furor-over-drug-prices-puts-patient-advocacy-groups-in-bind.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbWide.jpg", "legacy": {"wide": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/28/business/28PATIENTS/28PATIENTS-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1423", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Many groups ostensibly on the side of patients find themselves conflicted by the millions they receive from the pharmaceutical industry.", "pub_date": "2016-09-28T04:00:00+0000", "news_desk": "Business", "headline": {"print_headline": "Loyalties Split, Patient Groups Skip Drug Price Debate", "main": "Furor Over Drug Prices Puts Patient Advocacy Groups in Bind"}, "print_page": "1", "snippet": "Many groups ostensibly on the side of patients find themselves conflicted by the millions they receive from the pharmaceutical industry....", "_id": "57eb087a95d0e021d7988b70", "slideshow_credits": null, "abstract": "Country's largest patient advocacy groups have mostly avoided public debate over skyrocketing drug prices; many of these groups, which are hugely influence on Capitol Hill, get millions of dollars annually in donations from drug firms; critics say groups, by avoiding cost debate, are shirking patient-advocacy responsibilities. "}